Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer

  title={Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer},
  author={Ting-ting Wang and Mingming Lv and Su-nan Shen and Sheng Zhou and Ping Wang and Yueqiu Chen and Baorui Liu and Li-ke Yu and Yayi Hou},
  journal={PLoS ONE},
Objective MicroRNAs (miRNAs) expression is altered in cancer cells, and miRNAs could serve as diagnostic and prognostic biomarker for cancer patients. This study was designed to analyze circulating miRNAs expression in the malignant pleural effusion (MPE) and their association with patient survival in non-small cell lung cancer (NSCLC). Methods Pleural effusion from 184 patients with NSCLC and MPE were collected. MiRNA microarray and bioinformatics interpretation were used to evaluate miRNA… 

Figures and Tables from this paper

Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer.
The results suggest that serum miRNAs could serve as predictors of survival for advanced NSCLC.
Exosomal MicroRNA Expression Profiling in Patients with Lung Adenocarcinoma-associated Malignant Pleural Effusion
These miRNAs in exosomes in Ad-MPE and benign (non-neoplastic) pleural effusion (BPE) may have a diagnostic potential for differentiating Ad- MPE from BPE.
Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion
  • Yoon Mi Shin, J. Yun, K. Choe
  • Medicine, Biology
    Cancer research and treatment : official journal of Korean Cancer Association
  • 2014
It is suggested that the expression levels of circulating extracellular miRNAs that are deregulated in lung cancer in patients with pleural effusion may have diagnostic value when differentiating between LA-MPE and BPE.
miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives
The potential benefits of using extracellular miRNAs present in body fluids as part of the diagnostic evaluation of cancer include low invasiveness, and the repeatability and ease of obtaining the specimens, apart from the diagnostic applications of altered miRNA expression profiles.
Clinical Aspect of MicroRNA in Lung Cancer
  • H. Jeong
  • Biology, Medicine
    Tuberculosis and respiratory diseases
  • 2014
Recent researches regarding clinical applications of miRNAs in the diagnosis and management of lung cancer are summarized.
Serum MicroRNA‐150 Predicts Prognosis for Early‐Stage Non‐Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1
The findings suggest that miR‐150 binding on specific recognition sites in 3′ UTR of tumor suppressor gene SRCIN1 present a potential therapeutic target for NSCLC.
MicroRNAs – novel biomarkers for malignant pleural effusions
This work summarises the available information from recent years regarding the possibility of using miRNAs as biomarkers in the diagnosis of neoplasms and focused on malignant pleural effusions with an emphasis on non-small cell lung cancer (NSCLC).
TFIIB-Related Factor 2 Over Expression Is a Prognosis Marker for Early-Stage Non-Small Cell Lung Cancer Correlated with Tumor Angiogenesis
BRF2 is a promising biomarker to identify individuals with poor prognostic potential and a possible target for anti-angiogenic therapy for patients with early-stage NSCLC.
Clinical relevance of circulating cell-free microRNAs in cancer
The latest developments in the use of circulating microRNAs as prognostic and predictive biomarkers are considered and their utility in personalized medicine is discussed.


Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.
  • Zhibin Hu, X. Chen, Hongbing Shen
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
The four-miRNA signature from the serum may serve as a noninvasive predictor for the overall survival of NSCLC.
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.
Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions
This study demonstrated that cell-free miRNAs in the supernatant of effusions may aid in the diagnosis of malignancy and predict chemosensitivity to docetaxel.
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
MicroRNAs (miRNAs) have been identified as promising prognostic markers in non-small-cell lung cancer (NSCLC) since they play an important role in oncogenesis. The miR-34 family is composed of three
MicroRNA signature predicts survival and relapse in lung cancer.
Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis.
Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma.
This panel of 7 serum miRNAs holds promise as a novel blood-based biomarker for the diagnosis of ESCC, and clearly distinguished stage I/II ESCC patients from controls.
Exosomal microRNA: a diagnostic marker for lung cancer.
The significant difference in total exosome and miRNA levels between lung cancer patients and controls, and the similarity between the circulating exosomal miRNAs and the tumor-derived miRNA patterns, suggest that circulating exOSomal miRNA might be useful as a screening test for lung adenocarcinoma.